DEP remdesivir nanoparticle / Starpharma - LARVOL DELTA

Starpharma Receives $5.5M R&D Tax Incentive Refund (Starpharma Press Release) - "'Starpharma is pleased to announce the receipt of $5.5 million under the Australian Government’s R&D Tax Incentive program. This program is important in driving innovation and product development within our sector, enabling local companies to invest in addressing significant health challenges.'....'We are continuing to focus on translating this progress into tangible results that align with our three strategic priorities: maximising DEP asset value, accelerating early asset development, and building long-term sustainability.'"

Financing • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Infectious Disease • Novel Coronavirus Disease • Oncology • Ovarian Cancer • Solid Tumor

Starpharma creates slow release soluble DEP remdesivir nanoparticle (Businesswire) - "Starpharma...today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir....The solubility of DEP® remdesivir is 100‑fold higher than standard remdesivir. The benefit of DEP® remdesivir’s enhanced aqueous solubility is that it would enable subcutaneous injection rather than intravenous infusion, allowing for outpatient treatment and reducing the burden on hospitals."

Preclinical • Infectious Disease • Novel Coronavirus Disease